SNIPR Biome reports positive findings for first-in-human, CRISPR-based microbial gene therapy
Danish CRISPR-based microbial gene therapy company SNIPR Biome have announced positive interim data from its phase 1 clinical trial with SNIPR001.
SNIPR001 is a CRISPR-armed phage therapeutic which targets and removes E. coli, including antibiotic-resistant strains, from the human gastrointestinal tract. It is initially being looked at for patients with haematological malignancies who are undergoing haematopoietic stem cell transplants and are vulnerable to blood infections caused by the translocation of E. coli from the gut.
The study tested SNIPR001 in three levels of doses in 36 healthy people, with an aim to study the safety profile, SNIPR001 recovery and pharmacodynamics of the drug. The trial showed that oral dosing over seven days was well-tolerated and that SNIPR001 numerically lowered gut E. coli levels. SNIPR001 could also be recovered in faeces from treated individuals in a dose-dependent manner.
Dr Christian Grøndahl, CEO and co-founder of SNIPR Biome, commented: “We are thrilled with these positive interim results from our phase 1 clinical trial of SNIPR001, which provide clinical validation for this innovative treatment. With the combined killing effects of bacteriophages and CRISPR-Cas technology, SNIPR001 has demonstrated the ability to target and eliminate antibiotic-resistant E. coli strains in the gut, providing a safe alternative to traditional treatments that do not work against antibiotic-resistant strains, while sparing the rest of the gut microbiome. This is a significant milestone in our mission to develop ground-breaking solutions in the fight against antimicrobial resistance, and we look forward to advancing SNIPR001 through further clinical studies to learn more and ultimately, we hope, to improve patient outcomes.”
Acurx Pharmaceuticals announces positive data from phase 2b trial for C. difficile infection treatment
Acurx Pharmaceuticals has announced that it has discontinued its phase 2b clinical trial of its …
NMD Pharma has announced that the first patient has been dosed in its phase 2 …
AstraZeneca and Daiichi Sankyo have shared positive high-level results from the TROPION-Breast01 phase 3 trial, …